A new treatment protocol reducing the risk of implantation failure and early pregnancy loss after transfer of embryos resulting from in vitro fertilisatio
Not Applicable
Completed
- Conditions
- uteal phase insufficiency in assisted reproductionPregnancy and ChildbirthLuteal phase insufficiency
- Registration Number
- ISRCTN45835041
- Lead Sponsor
- MARGen Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 25
Inclusion Criteria
1. Women
2. Aged between 28 and 39 years,
3. Failed to become pregnant
4. Had low luteal-phase progesterone levels in a previous in vitro fertilization attempt
Exclusion Criteria
1. Age of >40 years
2. Andrological gynecological and systemic pathologies unrelated to the corpus luteum function:
2.1. Azoospermia
2.2. Necrozoospermia
2.3. Uterine polyps and fibroids
2.4. Polycystic ovary syndrome
2.5. Endometriosis
2.6. Cushing syndrome
2.7. Diabetes
2.8. Hypothyreosis and hyperthyreosis
2.9. Body mass index >29
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical pregnancy rate (number of pregnancies divided by the number of embryo transfer procedures) is measured from medical records 3 months after embryo transfer
- Secondary Outcome Measures
Name Time Method 1. Implantation rate (number of gestational sacs containing a living embryo implanted in the uterus divided by the number of embryos transferred) is measured from medical records 6 weeks after embryo transfer<br>2. Serum progesterone concentration is measured using immunoassay at the 7th and 14th day after embryo transfer<br>3. Total dose of progesterone administered is measured from medical records at the 14th day after embryo transfer